寿仙谷: 寿仙谷第五届监事会第二次会议决议公告

Meeting Overview - The second meeting of the fifth Supervisory Board of Zhejiang Shuxian Valley Pharmaceutical Co., Ltd. was held on August 27, 2025, with all three supervisors present [1] - The meeting was chaired by Ms. Xu Lingyan and complied with relevant regulations [1] Financial Report Approval - The Supervisory Board approved the 2025 semi-annual report, which accurately reflects the company's financial status and operational results, adhering to regulatory requirements [2] - The report was deemed to have no insider information leakage or other actions harming the company's interests [2] Fund Usage Report Approval - The Supervisory Board approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations [2] - The report accurately reflects the usage of raised funds and fulfills information disclosure obligations [2] Related Party Transactions - The Supervisory Board approved the proposal to increase the estimated amount of daily related party transactions for 2025, stating that these transactions are based on operational needs and do not harm the interests of the company or shareholders [3] - The pricing of transactions with related parties is not substantially different from that with non-related parties [3] Capital Change and Governance Structure - The Supervisory Board approved a proposal to change the company's registered capital and abolish the Supervisory Board, transferring its responsibilities to the Audit Committee of the Board [4] - The registered capital will change from 198,241,889.00 yuan to 198,243,911.00 yuan due to the conversion of bonds into shares [4] - The proposal requires approval at the company's first extraordinary general meeting of 2025 [4]